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Abstract
Preclinical studies indicate a link between the kynurenine pathway and monocyte chemoattractant protein-1 (MCP-1), but 
there is a lack of clinical studies examining this further. We here perform a secondary analysis of kynurenine metabolites and 
MCP-1 in cerebrospinal fluid of 23 twins affected from schizophrenia, bipolar disorder or unaffected. We show an association 
between MCP-1 and kynurenic acid (KYNA), driven by unique environmental influences and a less pronounced association 
between MCP-1 and tryptophan. No association was detected between MCP-1 and quinolinic acid. Further studies on the 
mechanism behind the putative relationship between KYNA and MCP-1 are needed.
Keywords Twin study · Cerebrospinal fluid · Biomarker · Kynurenic acid · Monocyte chemoattractant protein-1 · 
Chemokine ligand 2
Introduction
The kynurenine pathway is the major route for tryptophan 
(TRP) degradation and gives rise to neuroactive compounds 
like kynurenic acid (KYNA) and quinolinic acid (QUIN), 
displaying neuroprotective and neurotoxic properties, 
respectively [1]. Abnormalities in the kynurenine pathway 
have been linked to numerous brain disorders [2], includ-
ing psychiatric disorders such as schizophrenia and bipolar 
disorder [3].
Monocyte chemoattractant protein 1 (MCP-1), also 
known as chemokine ligand 2 (CCL2), is involved in the 
recruitment of macrophages to infection sites within the Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 6-019-01042 -9) contains 
supplementary material, which is available to authorized users.
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central nervous system (CNS) [4], and preclinical studies 
have demonstrated a relationship between MCP-1 and the 
kynurenine pathway. In mice, for example, reduction of 
indoleamine 2,3-dioxygenase (IDO)—the mediating enzyme 
of tryptophan degradation—resulted in lower MCP-1 lev-
els [5, 6], and plasma kynurenine correlated with MCP-1 
gene expression within the CNS [7]. In a study on in vitro 
cells of human monocytes, prior exposure to kynurenine 
had an enhancing effect on MCP-1-induced transmigration 
[8]. Although abnormal peripheral levels of MCP-1 have 
been associated with bipolar disorder [9, 10], and psychosis 
[9, 11], no studies have explored the relationship between 
MCP-1 and the kynurenine pathway within the human CNS.
To explore the role of MCP-1 in relation to the kynure-
nine pathway in a clinical sample, we here conduct a sec-
ondary analysis of previously published data. In the original 
reports, we analyzed CSF levels of TRP, KYNA, QUIN, 
Interleukin 6 (IL-6), IL-8, and tumor necrosis factor alpha 
(TNF-α) [12], and MCP-1 [13] in twins with psychiatric 
morbidity. We found mutual correlations of QUIN, IL-8, 
and TNF-α, and that higher CSF KYNA correlated with 
psychotic symptoms and personality traits [12]. Here, we 
analyze available CSF data from 23 monozygotic (MZ) or 
dizygotic (DZ) twins affected by schizophrenia or bipolar 
disorders. First, we estimate correlations between the CSF 
levels of MCP-1 and KYNA, TRP, QUIN, IL-6, IL-8, and 
TNF-α. Second, we analyze correlations in the MZ and DZ 
twin pairs to estimate the genetic and environmental effects.
Materials and methods
Study population
From the Schizophrenia and bipolar twin study in Sweden 
(STAR) [14], we had available kynurenine and MCP-1 CSF 
data on 25 same-sex individual twins (see flowchart in Sup-
plementary Fig. 1). We excluded two twins due to analysis 
failure, and for this report, complete data were available 
from 23 twins (10 complete pairs). The twins were clinically 
assessed with the Structured Clinical Interviews for DSM-IV 
Axis I and II (SCID I and II). Information on socioeconomic 
factors (e.g., education), smoking status, and age at disease 
onset were available. Zygosity determination (DNA analy-
sis) resulted in 12 MZ and 11 DZ twins [15].
The sampling of cerebrospinal fluid and blood
The CSF sampling occurred between March 2008 and Sep-
tember 2011 as described previously [16]. Lumbar punctures 
were performed in the morning by a clinical neurologist. 
The needle was inserted in vertebral interspace (L3–L5), 
in a sitting position and 12 mL of CSF was collected, and 
stored at − 80° Celsius pending analysis. Self-assessment 
scales for depression [Montgomery–Åsberg Depression 
Scale (MADRS-S)] and hypomania/mania [Young Ziegler 
Mania Rating Scale (YMRS)] were administered. Blood 
samples were drawn at 0800 h with subjects fasting. Height 
and weight were measured, and body mass index (BMI) 
calculated.
Analytical procedures
We refer to the Supplemental information for detailed 
descriptions of the analytical procedures including CSF/
serum albumin ratio, C-reactive protein (CRP) and CSF 
analyses of MCP-1, KYNA, TRP, QUIN, IL-6, Il-8, and 
TNF-α.
Statistical analyses
Sample characteristics are presented as percentages, means 
(standard deviations), or medians (maximum, minimum-
scores). CSF markers were transformed to standardized 
scores (mean = 0, SD = 1). Associations of mean values 
between CSF markers were analyzed with linear regression 
with a cluster-robust sandwich estimator (which accounts 
for the dependency between the twin pairs when estimating 
the standard errors). Adjustments were made for sex, age 
at CSF sampling, psychiatric diagnosis (i.e., schizophre-
nia with or without affective features, or bipolar disorder), 
and smoking status. In the twin analyses, for each marker, 
within-twin pairs differences were calculated (twin 1–twin 
2) in complete pairs (n = 10). We regressed the within-pair 
differences for each marker using a conditional linear regres-
sion model (fixed effects regression) with a cluster-robust 
sandwich estimator for the pairs. For multiple testing, we 
used Bonferroni correction yielding the limit p value < 0.003 
based on the total amount of CSF markers (n = 17) that were 
previously analyzed. Statistical analyses were performed in 
STATA 15.1.
Interpretation
To disentangle shared environmental and genetic mecha-
nisms, associations between the within-pair differences of 
two markers were analyzed in MZ and DZ pairs separately. 
An equal or higher regression coefficient in MZ twins than 
in DZ twins was interpreted as influence from  the unique 
environment. A higher regression coefficient in DZ twins 
was interpreted as genetic influences.
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Ethical considerations
The study was approved by the Ethical Review Board, 
Stockholm (Dnr: 2004-448; 2007-779), and was performed 
in compliance with the Helsinki Declaration.
Results
For demographics and clinical characteristics, see Table 1. 
CSF concentrations of MCP-1, kynurenine metabolites, 
cytokines, and descriptive statistics for this cohort have been 
Table 1  Demographic and 
clinical characteristics of the 
twin sample (n = 23 individual 
twins)
SD standard deviation, CRP C-reactive protein, MADRS-S self-rated Montgomery–Åsberg Depression Rat-
ing Scale, YMRS Young Ziegler Mania Rating Scale, MCP-1 monocyte chemoattractant protein 1, KYNA 
kynurenic acid, TRP tryptophan, QUIN quinolinic acid, IL interleukin, TNF-α tumor necrosis factor alpha
a Five complete twin pairs. In two twin pairs, CSF data was available from one of the twins in the pair
b Five complete twin pairs. In one twin pair, one of the twins participated in the CSF sampling
c Types of antipsychotics: haloperidol, levomepromazine, olanzapine, perphenazine, quetiapine, or risperi-
done
Monozygotic twins Dizygotic twins
n = 12a n = 11b
n (%) n (%)
Sex
 Males 5 (41.67) 8 (72.73)
 Females 7 (58.33) 3 (27.27)
Age at sampling, in years, median (min–max) 55 (50–65) 56 (38–58)
Completed education
 Elementary school 4 (33.33) 4 (36.36)
 High school (2 years) 3 (25) 1 (9.09)
 High school (3 years) 2 (16.67) 2 (18.18)
 University 3 (25) 3 (27.27)
 Unknown 1 (9.09)
Smoker 4 (33.33) 4 (36.36)
Diagnosis
 Schizophrenia 1 (8.33) 2 (18.18)
 Schizophrenia with affective features 2 (16.67) 1 (9.09)
 Bipolar disorder 1 (8.33) 1 (9.09)
 Not affected 8 (66.67) 7 (63.64)
Type of twin pair
 Concordant schizophrenia 2 (16.67) 2 (18.18)
 Discordant schizophrenia 3 (25) 2 (18.18)
 Discordant bipolar disorder 3 (25) 3 (27.27)
 Not affected 4 (33.33) 4 (36.36)
Age at onset in years, median (min–max) 29.5 (16–55) 28.0 (19–54)
Clinical parameters
 Body mass index, median (min–max) 28.2 (7.5) 29.7 (7.5)
 Albumin ratio, mean (SD) 7.3 (3.2) 5.3 (2.1)
 CRP, mean (SD) 6.4 (6.7) 4.2 (5.7)
Assessment scales at sampling
 MADRS-S, mean (SD) 2.0 (3.0) 2.7 (3.4)
 YMRS, mean (SD) 0.2 (0.4) 1.3 (3.0)
Medication
 Antipsychoticsc 4 (33.33) 4 (36.36)
 Antidepressants 4 (33.33) 4 (36.36)
 Antiepileptics 0 (0) 2 (18.18)
 Lithium 0 (0) 0 (0)
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reported previously [12, 13]. The markers were analyzed in 
a linear regression model in all twins (n = 23). After adjust-
ments for age, sex, smoking, and any psychiatric diagnosis 
(schizophrenia/bipolar disorder), higher MCP-1 was associ-
ated with higher KYNA and TRP (Table 2). There was no 
association between MCP-1 and QUIN. For complete results 
of all CSF markers, see Supplementary Table 1.
Within-pair differences of MCP-1 and kynurenine 
metabolites and cytokines were analyzed in the MZ pairs 
(n = 5) taking shared environmental and genetic factors 
into account, and the DZ pairs (n = 5) accounting for 
shared environmental factors. The within-pair differences 
between MCP-1 and KYNA were significantly associated, 
and the regression coefficient was higher in the MZ than 
in the DZ pairs (Table 3), which remained significant after 
correcting for multiple testing. In Fig. 1, the regression 
coefficients for MCP-1 and KYNA are presented from the 
overall analysis and the DZ and MZ analyses, respectively. 
Within-pair differences between MCP-1 and TRP were 
associated in the DZ but not in the MZ pairs (Table 3). 
Associations found between MCP-1 and TNF-α or IL-8 
did not survive adjustments for multiple testing (Table 3). 
Antidepressant treatment was associated with higher 
Table 2  Association between 
monocyte chemoattractant 
protein-1 (MCP-1) and 
kynurenine metabolites and 
cytokines in cerebrospinal fluid 
(CSF)
Results from the linear regression analysis of the mean values in all twins
Model 1: Adjusted for age and sex. Model 2: Adjusted for age, sex, diagnosis of schizophrenia or bipolar 
disorder and smoking
All variables were standardized [mean = 0, standard deviation (SD) = 1]. Linear regression was applied 
with a cluster-robust sandwich estimator for the standard errors to account for the twin pair relationships. 
Results presented as the regression coefficient (Reg. coef.) with 95% confidence intervals (CI)
*Indicates that the p values are significant after Bonferroni correction (p value < 0.003)
Biomarkers N MCP-1 p value MCP-1 p value
Model 1 Model 2
Reg. coef. (95% CI) Reg. coef. (95% CI)
Tryptophan (TRP) 23 0.40 (0.14, 0.65) 0.006 0.37 (0.16, 0.58) 0.002*
Kynurenic acid (KYNA) 23 0.48 (0.25, 0.70) 0.001* 0.45 (0.19, 0.71) 0.002*
Quinolinic acid (QUIN) 23 0.16 (− 0.15, 0.46) 0.28 0.049 (− 0.29, 0.39) 0.76
Interleukin 6 (IL 6) 23 − 0.22 (− 0.42, − 0.017) 0.036 − 0.087 (− 0.37, 0.20) 0.52
Interleukin 8 (IL-8) 23 0.022 (− 0.32, 0.36) 0.89 − 0.014 (− 0.36, 0.33) 0.93
Tumor necrosis factor 
alpha (TNF-α)
23 − 0.12 (− 0.58, 0.34) 0.58 − 0.12 (− 0.49, 0.25) 0.50
Table 3  Association between 
monocyte chemoattractant 
protein-1 (MCP-1) and 
kynurenine metabolites and 
cytokines in cerebrospinal fluid 
(CSF)
Results from the conditional linear regression analysis of the differences within the complete twin pairs
All variables were standardized [mean = 0, standard deviation (SD) = 1]. Conditional linear regression 
was used for analysis, with cluster-robust sandwich estimator for standard errors. Results presented as the 
regression coefficient (Reg. Coef.) with 95% confidence intervals (CI). We interpreted that a higher coef-
ficient in the MZ pairs than in the DZ pairs, was an effect from unique environmental factors, and a higher 
coefficient in the DZ pairs than in the MZ pairs as an effect from genetic factors
*Indicates that the p values are significant after Bonferroni correction (p value < 0.003)
CSF-markers Within-pair differences—MZ pairs 
(n = 5)
Within-pair differences—DZ pairs 
(n = 5)
MCP-1 MCP-1
Reg. Coef. (95% CI) p value Reg. Coef. (95% CI) p value
Tryptophan (TRP) − 0.52 (− 2.32, 1.28) 0.51 0.51 (0.24, 0.79) 0.005
Kynurenic acid (KYNA) 1.03 (0.64, 1.42) 0.001* 0.59 (0.33, 0.85) 0.002*
Quinolinic acid (QUIN) 0.11 (− 0.84, 1.05) 0.79 0.02 (− 3.92, 3.95) 0.99
Interleukin 6 (IL 6) 0.14 (− 0.04, 0.32) 0.12 1.38 (− 4.48, 7.24) 0.57
Interleukin 8 (IL-8) − 0.49 (− 0.94, − 0.04) 0.037 − 2.06 (− 5.47, 1.34) 0.18
Tumor Necrosis Factor 
alpha (TNF-α)
− 0.48 (− 0.74, − 0.22) 0.004 − 1.25 (− 3.65, 1.16) 0.24
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MCP-1 levels (data not shown). To account for this, we 
excluded twins with ongoing antidepressant medication, 
which did not change the main results (data not shown).
Discussion
We here report evidence for a link between the inflammatory 
markers MCP-1 and KYNA in the CNS. We show an overall 
association between MCP-1 and KYNA in CSF, conceiv-
ably driven by unique environmental influences according 
to the twin analysis. There was a less pronounced associa-
tion between MCP-1 and TRP overall, but the twin analysis 
demonstrated that genetic factors may account for the cor-
relation. Notably, we did not find any association between 
MCP-1 and QUIN.
It has long been known that the immune system activates 
tryptophan degradation via the kynurenine pathway [17]. 
Particularly, interferon gamma (IFN-γ), but also neopterin, a 
marker for IFN-γ activity [18], have been associated with an 
upregulation of several neuroactive kynurenine metabolites 
such as KYNA and QUIN in CSF [19, 20]. In accordance 
with our findings, studies on rodents showed that manipula-
tion of TRP degradation affects MCP-1 levels [7, 5, 6, 8] 
and MCP-1 seems to play a role in neurotransmission such 
as dopamine release [21]. Clinical CSF studies on kynure-
nine metabolites and inflammatory markers are rare. Yet, 
one study analyzed CSF from hepatitis C-affected patients 
on interferon alpha (INF-α) treatment, and found trend-level 
associations between KYNA and MCP-1. Contrasting our 
findings, they found a correlation between QUIN and MCP-1 
[22], but might be due to the massive inflammatory response 
induced by the INF-α treatment [23].
The major strength of this study is the unique sampling 
of CSF from twins, which allowed us to disentangle genetic 
and environmental factors. However, the sample size is 
small, and some participants were affected by psychiatric 
conditions and/or had ongoing medication, which may affect 
the CSF marker levels. The results must, therefore, be con-
sidered as indicative and interpreted with caution.
To conclude, by analyzing CSF from twins, we suggest 
that brain KYNA contributes to higher MCP-1 levels or vice 
versa. Further studies are required to determine a causal rela-
tionship between KYNA and MCP-1.
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